Design, Synthesis, and Antiviral Activity of the Thiazole Positional Isomers of a Potent HIV-1 Entry Inhibitor NBD-14270

被引:7
|
作者
Kurkin, Alexander, V [1 ]
Curreli, Francesca [2 ]
Iusupov, Ildar R. [1 ]
Spiridonov, Evgeniy A. [1 ]
Ahmed, Shahad [2 ]
Markov, Pavel O. [1 ]
Manasova, Ekaterina, V [1 ]
Altieri, Andrea [1 ]
Debnath, Asim K. [2 ]
机构
[1] EDASA Sci Srls, Via Stingi 37, I-66050 San Salvo, CH, Italy
[2] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Mol Modeling & Drug Design, 310 E 67th St, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
Docking; HIV-1; gp120; NBD compounds; reverse transcriptase; thiazole isomers; IMMUNODEFICIENCY-VIRUS TYPE-1; FUSION INHIBITOR; CCR5; CORECEPTOR; NEUTRALIZATION; MARAVIROC; ENVELOPE; BINDING; OPTIMIZATION; ENFUVIRTIDE; ANTAGONIST;
D O I
10.1002/cmdc.202200344
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The envelope glycoprotein gp120 of human immunodeficiency virus type 1 (HIV-1) plays a critical role in virus entry to the cells by binding to the host cellular protein CD4. Earlier, we reported the design and discovery of a series of highly potent small-molecule entry antagonists containing a thiazole ring (Scaffold A). Since this thiazole ring connected with an ethyl amide linkage represents the molecule's flexible part, we decided to explore substituting Scaffold A with two other positional isomers of the thiazole ring (Scaffold B and C) to evaluate their effect on the antiviral potency and cellular toxicity. Here we report the novel synthesis of two sets of positional thiazole isomers of the NBD-14270 by retrosynthetic analysis approach, their anti-HIV-1 activity, cellular toxicity, and structure-activity relationships. The study revealed that Scaffold A provided the best HIV-1 inhibitors with higher potency and better selectivity index (SI).
引用
收藏
页数:17
相关论文
共 50 条
  • [21] OPTIMIZATION OF A POTENT HIV-1 INTEGRASE STRAND TRANSFER INHIBITOR (INSTI): MOLECULAR MODELING, SYNTHESIS AND ANTI-HIV ACTIVITY
    De Grazia, Sara
    Ferro, Stefania
    De Luca, Laura
    Barreca, Maria Letizia
    Debyser, Zeger
    Chimirri, Alba
    DRUGS OF THE FUTURE, 2009, 34 : 140 - 140
  • [22] A SYNTHETIC HIV-1 PROTEASE INHIBITOR WITH ANTIVIRAL ACTIVITY ARRESTS HIV-LIKE PARTICLE MATURATION
    MCQUADE, TJ
    TOMASSELLI, AG
    LIU, L
    KARACOSTAS, V
    MOSS, B
    SAWYER, TK
    HEINRIKSON, RL
    TARPLEY, WG
    SCIENCE, 1990, 247 (4941) : 454 - 456
  • [23] Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
    Tsiang, Manuel
    Jones, Gregg S.
    Goldsmith, Joshua
    Mulato, Andrew
    Hansen, Derek
    Kan, Elaine
    Tsai, Luong
    Bam, Rujuta A.
    Stepan, George
    Stray, Kirsten M.
    Niedziela-Majka, Anita
    Yant, Stephen R.
    Yu, Helen
    Kukolj, George
    Cihlar, Tomas
    Lazerwith, Scott E.
    White, Kirsten L.
    Jin, Haolun
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (12) : 7086 - 7097
  • [24] Synthesis of 5-Arylpyrrole-2-carboxylic Acids as Key Intermediates for NBD Series HIV-1 Entry Inhibitors
    Belov, Dmitry S.
    Ivanov, Vladimir N.
    Curreli, Francesca
    Kurkin, Alexander V.
    Altieri, Andrea
    Debnath, Asim K.
    SYNTHESIS-STUTTGART, 2017, 49 (16): : 3692 - 3699
  • [25] Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity
    Zhu, Yuanmei
    Chong, Huihui
    Yu, Danwei
    Guo, Yan
    Zhou, Yusen
    He, Yuxian
    JOURNAL OF VIROLOGY, 2019, 93 (11)
  • [26] Potent Inhibition of HIV-1 Entry with a Chemically Programmed Antibody Aided by an Efficient Organocatalytic Synthesis
    Gavrilyuk, Julia
    Uehara, Hisatoshi
    Otsubo, Nobumasa
    Hessell, Ann
    Burton, Dennis R.
    Barbas, Carlos F., III
    CHEMBIOCHEM, 2010, 11 (15) : 2113 - 2118
  • [27] SYNTHESIS OF HEXAHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AND THEIR HIV-1 ANTIVIRAL ACTIVITY
    Mohlala, Reagan Lehlogonolo
    Coyanis, Elena Mabel
    Fish, Muhammad Qasim
    Bode, Moira Leanne
    HETEROCYCLES, 2022, 104 (05) : 894 - 916
  • [28] Expeditious Synthesis of a Potent Allosteric HIV-1 Integrase Inhibitor GSK3839919A
    Bobko, Mark A.
    Elward, Jennifer M.
    Naidu, B. Narasimhulu
    Nieves-Quinones, Yexenia E.
    Reiher, Christopher A.
    Su, Qiaogong
    Sun, Liang
    Woodard, John
    Xie, Shiping
    Yang, Wuxing
    Yin, Yunxing
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2023, : 217 - 226
  • [29] Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization
    LaLonde, Judith M.
    Le-Khac, Matthew
    Jones, David M.
    Courter, Joel R.
    Park, Jongwoo
    Schoen, Arne
    Princiotto, Amy M.
    Wu, Xueling
    Mascola, John R.
    Freire, Ernesto
    Sodroski, Joseph
    Madani, Navid
    Hendrickson, Wayne A.
    Smith, Amos B., III
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (03): : 338 - 343
  • [30] Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
    Dwyer, John J.
    Wilson, Karen L.
    Davison, Donna K.
    Freel, Stephanie A.
    Seedorff, Jennifer E.
    Wring, Stephen A.
    Tvermoes, Nicolai A.
    Matthews, Thomas J.
    Greenberg, Michael L.
    Delmedico, Mary K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (31) : 12772 - 12777